Does the calcineurin inhibitor have influence on cytomegalovirus infection in heart transplantation?

Clinical Transplantation

Volumn 28, Issue 1, 2014, Pages 88-95

  Rodríguez Serrano, María ^a   Sánchez Lázaro, Ignacio ^a   Almenar Bonet, Luis ^a   Martínez Dolz, Luis ^a   Portolés Sanz, Manuel ^a   Rivera Otero, Miguel ^a   Salvador Sanz, Antonio ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Calcineurin inhibitor; CMV infection; Cyclosporine; Heart transplantation; Tacrolimus

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VALGANCICLOVIR;

ADULT; ARTICLE; BACTERIAL INFECTION; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EVENT FREE SURVIVAL; FEMALE; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL TIME; VIRUS LOAD;

CALCINEURIN INHIBITOR; CMV INFECTION; CYCLOSPORINE; HEART TRANSPLANTATION; TACROLIMUS;

ADULT; ANTIVIRAL AGENTS; CALCINEURIN; CYCLOSPORINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TACROLIMUS;

EID: 84892436344     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12282     Document Type: Article

References (39)

1. Almenar L, Segovia J, Crespo-Leiro MG et al. Spanish registry on heart transplantation. 22nd official report of the Spanish Society of Cardiology Working Group on Heart Failure and Heart Transplantation (1984-2010). Rev Esp Cardiol 2011: 64: 1138.
2. Sánchez-Lázaro IJ, Almenar L, Blanes M et al. Timing, etiology, and location of first infection in first year after heart transplantation. Transplant Proc 2010: 42: 3017.
3. Muñoz P, Fernández NS, Fariñas MC. Epidemiology and risk factors of infections after solid organ transplantation. Enferm Infecc Microbiol Clin 2012: 2: 10.
4. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005: 40: 704.
5. Snydman DR, Limaye AP, Potena L, Zamora MR. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 2011: 43(3 Suppl): S1.
6. Navarro-Manchón J, Martínez-Dolz L, Almenar Bonet L et al. Predictors of renal dysfunction at 1 year in heart transplant patients. Transplantation 2010: 27: 977.
7. De la Torre-Cisneros J, Fariñas MC, Castón JJ et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011: 29: 735.
8. Fateh-Moghadam S, Bocksch W, Wessely R, Jäger G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 2003: 76: 1470.
9. Kotton CN, Kumar D, Caliendo AM et al. Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010: 89: 779.
10. Delgado JF, Manito N, Almenar L et al. Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study. Transpl Infect Dis 2011: 13: 136.
11. Costanzo MR, Dipchand A, Starling R et al. International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010: 29: 914.
12. Satoh S, Tada H, Murakami M et al. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation. Transplant Proc 2005: 37: 1751.
13. Eisen HJ, Kobashigawa J, Keogh A et al. Mycophenolate Mofetil Cardiac Study Investigators. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005: 24: 517.
14. Hill JA, Hummel M, Starling RC et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007: 84: 1436.
15. Campistol JM, de Fijter JW, Nashan B, Holdaas H, Vítko Š, Legendre C. Everolimus and long-term outcomes in renal transplantation. Transplantation 2011: 92: S3.
16. Sánchez-Lázaro IJ, Almenar L, Martínez-Dolz L et al. A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation. Clin Transplant 2011: 25: 606.
17. Kobashigawa JA, Tobis JM, Starling RC et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005: 45: 1532.
18. Tuzcu EM, Kapadia SR, Sachar R et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005: 45: 1538.
19. Kanter J, Pallardó L, Gavela E et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome. Transplant Proc 2009: 41: 2156.
20. Linares L, Sanclemente G, Cervera C et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc 2011: 43: 2145.
21. Ye F, Ying-Bin X, Yu-Guo W, Hetzer R. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. J Heart Lung Transpl 2009: 28: 58.
22. Martínez-Dolz L, Almenar L, Martínez-Ortiz L et al. Predictive factors for development of diabetes mellitus post-heart transplant. Transplant Proc 2005: 37: 4064.
23. Jiang H, Wynn C, Pan F, Ebbs A, Erickson LM, Kobayashi M. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002: 73: 1808.
24. Khanna A, Cairns V, Hosenpud JD. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation 1999: 67: 614.
25. Shin GT, Khanna A, Ding R et al. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation 1998: 65: 313.
26. Meiser BM, Groetzner J, Kaczmarek I et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Trasplantation 2004: 78: 591.
27. Taylor DO, Barr ML, Radovancevic B et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Tranplant 1999: 18: 336.
28. Penninga L, Møller CH, Gustafsson F, Steinbrüchel DA, Gluud C. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Eur J Clin Pharmacol 2010: 66: 1177.
29. Grimm M, Rinaldi M, Yonan NA et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant 2006: 6: 1387.
30. Van de Beek D, Kremers WK, Del Pozo JL et al. Effect of infectious diseases on outcome after heart transplant. Mayo Clin Proc 2008: 83: 304.
31. Pollock-BarZiv SM, Dipchand AI, McCrindle BW et al. Randomized clinical trial of tacrolimus- vs cyclosporine-based immunosuppression in pediatric heart transplantation: preliminary results at 15-month follow-up. J Heart Lung Transplant 2005: 24: 190.
32. Guethoff S, Meiser BM, Groetzner J et al. Ten-year results of A randomized trial comparing tacrolimus versus cyclosporine A in combination with mycophenolate mofetil after heart transplantation. Transplantation 2013: 95: 629.
33. Meylan PR, Manuel O. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr Opin Infect Dis 2007: 20: 412.
34. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplantation 2008: 8: 2111.
35. Kobashigawa JA, Patel J, Furukawa H et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006: 25: 434.
36. Sánchez-Lázaro IJ, Almenar-Bonet L, Martínez-Dolz L et al. Preliminary results of a prospective randomized study of cyclosporine versus tacrolimus in the development of cardiac allograft vasculopathy at 1 year after heart transplantation. Transplant Proc 2010: 42: 3199.
37. Stehlik J, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report - 2010. J Heart Lung Transplant 2010: 29: 1089.
38. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008: 117: 2131.
39. Stehlik J, Edwards LB, Kucheryavaya AY et al. The registry of the international society for heart and lung transplantation: twenty-eighth adult heart transplant report-2011. J Heart Lung Transplant 2011: 30: 1078.